1
|
Cencini E, Fabbri A, Schiattone L, Gentili F, Mazzei MA, Bocchia M. Durable response after VNCOP-B and rituximab in an elderly patient with high-grade B-cell lymphoma. Acta Clin Belg 2018; 73:408-412. [PMID: 29212420 DOI: 10.1080/17843286.2017.1412888] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
Abstract
OBJECTIVES AND METHODS High-grade B-cell lymphoma, NOS (HGBL) have an aggressive clinical behavior and poor outcome using regimens currently employed for diffuse large B-cell lymphoma (DLBCL) such as rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP). Promising results have been reported with more intensive regimens but this strategy is not suitable for elderly or unfit patients. Rituximab in association with cyclophosphamide, mitoxantrone, vincristine, etoposide, bleomycin, and prednisone (R-VNCOP-B) demonstrated high efficacy and manageable toxicity as first-line treatment for elderly aggressive non-Hodgkin lymphoma patients. RESULTS AND CONCLUSION In this case study, we report the rapid improvement, long-lasting complete remission, and mild toxicity of R-VNCOP-B regimen in an elderly, triple-expressor HGBL patient, with aggressive disease and poor-risk profile.
Collapse
Affiliation(s)
- Emanuele Cencini
- Unit of Hematology, Azienda Ospedaliera Universitaria Senese, Siena, Italy
- Unit of Hematology, University of Siena, Siena, Italy
| | - Alberto Fabbri
- Unit of Hematology, Azienda Ospedaliera Universitaria Senese, Siena, Italy
| | - Luana Schiattone
- Unit of Hematology, Azienda Ospedaliera Universitaria Senese, Siena, Italy
| | - Francesco Gentili
- Department of Medical, Surgical and Neuro Sciences, Diagnostic Imaging, Azienda Ospedaliera Universitaria Senese, Siena, Italy
| | - Maria Antonietta Mazzei
- Department of Medical, Surgical and Neuro Sciences, Diagnostic Imaging, Azienda Ospedaliera Universitaria Senese, Siena, Italy
| | - Monica Bocchia
- Unit of Hematology, Azienda Ospedaliera Universitaria Senese, Siena, Italy
- Unit of Hematology, University of Siena, Siena, Italy
| |
Collapse
|
2
|
Cencini E, Fabbri A, Lauria F, Bocchia M. Long-term efficacy and toxicity of rituximab plus fludarabine and mitoxantrone (R-FM) for gastric marginal zone lymphoma: a single-center experience and literature review. Ann Hematol 2018; 97:821-829. [PMID: 29340761 DOI: 10.1007/s00277-018-3243-7] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/24/2017] [Accepted: 01/06/2018] [Indexed: 11/28/2022]
Abstract
There is no consensus about the best treatment option for patients with HP-negative gastric MALT lymphomas or persistent disease after HP eradication.We have investigated fludarabine and mitoxantrone with rituximab (R-FM) as first-line treatment. A cohort of 13 patients was analyzed. Induction treatment consisted of fludarabine (25 mg/m2 i.v. on days 2 to 4), mitoxantrone (10 mg/m2 i.v. on day 2), and rituximab (375 mg/m2 i.v. on day 1), for up to six cycles every 28 days. All patients achieved a complete remission, a median of four cycles was given. Treatment-related toxicities were mainly hematologic, with grade 3-4 neutropenia observed in 11/13 patients (84.6%). One patient had grade 3 febrile neutropenia, two patients developed prolonged pancytopenia (15%), and one patient experienced CMV reactivation at 2 months. After a median follow-up of 84 months, 1/13 had disease relapse and received total gastrectomy; estimated 10-year progression-free survival and overall survival were 92.4 and 100%, respectively. Our study suggests R-FM regimen has a high long-term efficacy for untreated HP-negative gastric MALT lymphoma patients and HP-positive patients who failed HP eradication. The elevated incidence of grade 3-4 hematological toxicity, yet manageable, makes this treatment less safe compared to rituximab in combination with chlorambucil or bendamustine.
Collapse
Affiliation(s)
- Emanuele Cencini
- Haematology Unit, Azienda Ospedaliera Universitaria Senese, Viale Bracci, 16, 53100, Siena, Italy. .,University of Siena, Siena, Italy.
| | - Alberto Fabbri
- Haematology Unit, Azienda Ospedaliera Universitaria Senese, Viale Bracci, 16, 53100, Siena, Italy
| | | | - Monica Bocchia
- Haematology Unit, Azienda Ospedaliera Universitaria Senese, Viale Bracci, 16, 53100, Siena, Italy.,University of Siena, Siena, Italy
| |
Collapse
|
3
|
Cencini E, Fabbri A, Schiattone L, Bartalucci G, Bocchia M. Low-dose chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab in follicular lymphoma. Eur J Haematol 2015; 94:277-278. [PMID: 25080977 DOI: 10.1111/ejh.12428] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/03/2023]
Affiliation(s)
- Emanuele Cencini
- Division of Haematology, University Hospital of Siena, Siena, Italy
| | | | | | | | | |
Collapse
|
4
|
Hojjat-Farsangi M. Novel and emerging targeted-based cancer therapy agents and methods. Tumour Biol 2015; 36:543-56. [PMID: 25663495 DOI: 10.1007/s13277-015-3184-x] [Citation(s) in RCA: 26] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/12/2014] [Accepted: 01/27/2015] [Indexed: 02/06/2023] Open
Abstract
After several decades of uncovering the cancer features and following the improvement of therapeutic agents, however cancer remains as one of the major reasons of mortality. Chemotherapy is one of the main treatment options and has significantly improved the overall survival of cancer patients, but chemotherapeutic agents are highly toxic for normal cells. Therefore, there is a great unmet medical need to develop new therapeutic principles and agents. Targeted-based cancer therapy (TBCT) agents and methods have revolutionized the cancer treatment efficacy. Monoclonal antibodies (mAbs) and small molecule inhibitors (SMIs) are among the most effective agents of TBCT. These drugs have improved the prognosis and survival of cancer patients; however, the therapeutic resistance has subdued the effects. Several mechanisms lead to drug resistance such as mutations in the drug targets, activation of compensatory pathways, and intrinsic or acquired resistance of cancer stem cells. Therefore, new modalities, improving current generation of inhibitors and mAbs, and optimizing the combinational therapy regimens are necessary to decrease the current obstacles in front of TBCT. Moreover, the success of new TBCT agents such as mAbs, SMIs, and immunomodulatory agents has sparked further therapeutic modalities with novel targets to inhibit. Due to the lack of cumulative information describing different agents and methods of TBCT, this review focuses on the most important agents and methods of TBCT that are currently under investigation.
Collapse
Affiliation(s)
- Mohammad Hojjat-Farsangi
- Department of Oncology-Pathology, Immune and Gene therapy Lab, Cancer Center Karolinska (CCK), Karolinska University Hospital Solna and Karolinska Institute, SE-171 76, Stockholm, Sweden,
| |
Collapse
|
5
|
Shah N, Tam C, Seymour JF, Rule S. How applicable is fludarabine, cyclophosphamide and rituximab to the elderly? Leuk Lymphoma 2014; 56:1599-610. [DOI: 10.3109/10428194.2014.963083] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/18/2022]
|
6
|
Olszewski AJ, Shafqat H, Ali S. Disparate survival outcomes after front-line chemoimmunotherapy in older patients with follicular, nodal marginal zone and small lymphocytic lymphoma. Leuk Lymphoma 2014; 56:942-50. [PMID: 24956144 DOI: 10.3109/10428194.2014.936013] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
Abstract
Using Surveillance, Epidemiology and End Results (SEER)-Medicare data (1996-2010), we compared survival and toxicity outcomes in 6993 patients older than 65 years with follicular (FL), nodal marginal zone (NMZL) and small lymphocytic lymphoma (SLL) receiving front-line therapy with rituximab (R), RCHOP (R, cyclophosphamide, doxorubicin, vincristine, prednisone), RCVP (R, cyclophosphamide, vincristine, prednisone) or R-fludarabine-containing regimens within 3 years from diagnosis. We demonstrated significant heterogeneity by histology after various regimens in multivariable survival models. Compared with RCHOP, overall survival was inferior with fludarabine-based regimens in FL (hazard ratio [HR] 1.53, p = 0.0001) and NMZL (HR 1.88, p = 0.0018). Conversely, in SLL outcomes were similar with any regimen. In NMZL and SLL, survival was not significantly different after single-agent R compared with multi-agent combinations. Choice of front-line chemotherapy may thus impact survival in older patients with indolent lymphomas, and heterogeneity by histology should be accounted for in clinical trials.
Collapse
Affiliation(s)
- Adam J Olszewski
- Division of Hematology-Oncology, Memorial Hospital of Rhode Island , Pawtucket, RI , USA
| | | | | |
Collapse
|
7
|
De la Cruz Vicente F, Carrillo-Cruz E, Rodriguez MS, Marín Niebla A, Galiana MLM, Gonzalez JF, Cuadrado IM, Campos JG, Tocino IE, Rios-Herranz E, Perez-Simón JA. Fludarabine, cyclophosphamide and rituximab as first-line treatment in patients with newly diagnosed follicular lymphoma. Eur J Haematol 2014; 93:469-75. [DOI: 10.1111/ejh.12384] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 05/11/2014] [Indexed: 11/29/2022]
Affiliation(s)
- Fátima De la Cruz Vicente
- Hospital Universitario Virgen del Rocío; Instituto de Biomedicina de Sevilla (IBIS)/CSIC/Universidad de Sevilla; Sevilla Spain
| | - Estrella Carrillo-Cruz
- Hospital Universitario Virgen del Rocío; Instituto de Biomedicina de Sevilla (IBIS)/CSIC/Universidad de Sevilla; Sevilla Spain
| | - Maria Sole Rodriguez
- Hospital Universitario Virgen del Rocío; Instituto de Biomedicina de Sevilla (IBIS)/CSIC/Universidad de Sevilla; Sevilla Spain
| | | | - Maria Luz Martino Galiana
- Hospital Universitario Virgen del Rocío; Instituto de Biomedicina de Sevilla (IBIS)/CSIC/Universidad de Sevilla; Sevilla Spain
| | - Jose Falantes Gonzalez
- Hospital Universitario Virgen del Rocío; Instituto de Biomedicina de Sevilla (IBIS)/CSIC/Universidad de Sevilla; Sevilla Spain
| | - Isabel Montero Cuadrado
- Hospital Universitario Virgen del Rocío; Instituto de Biomedicina de Sevilla (IBIS)/CSIC/Universidad de Sevilla; Sevilla Spain
| | - Jose Gonzalez Campos
- Hospital Universitario Virgen del Rocío; Instituto de Biomedicina de Sevilla (IBIS)/CSIC/Universidad de Sevilla; Sevilla Spain
| | - Ildefonso Espigado Tocino
- Hospital Universitario Virgen del Rocío; Instituto de Biomedicina de Sevilla (IBIS)/CSIC/Universidad de Sevilla; Sevilla Spain
| | | | - Jose Antonio Perez-Simón
- Hospital Universitario Virgen del Rocío; Instituto de Biomedicina de Sevilla (IBIS)/CSIC/Universidad de Sevilla; Sevilla Spain
| |
Collapse
|